(Q50856533)

24 March 2018

review article

1 reference

title

Low-grade serous carcinoma of the ovary or peritoneum. (English)

1 reference

24 March 2018

low-grade serous carcinoma

1 reference

0 references

0 references

0 references

D M Gershenson

1

1 reference

24 March 2018

publication date

1 April 2016

1 reference

24 March 2018

published in

Annals of Oncology

1 reference

24 March 2018

volume

27 Suppl 1

1 reference

24 March 2018

page(s)

i45-i49

1 reference

24 March 2018

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Low-grade serous tumors of ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Survival in women with grade 1 serous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

MEK in cancer and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

MEK1/2 inhibitors in the treatment of gynecologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW085

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDW085

1 reference

24 March 2018

1 reference

24 March 2018